Abbisko Cayman Limited (SEHK: 2256)
Health Care · Biotechnology · CN
HK$7.89
-9.83% today · -52.7% 1Y
Abbisko Cayman Limited (SEHK: 2256) operates in the Biotechnology industry within the Health Care sector. The company is valued at $665.94M and employs 286 people.
Over the last twelve months the share price has lost 52.7%, trading between 7.67 and 18.00.
Tweenvest scores Abbisko Cayman Limited across four factors: quality 53/100, value 72/100. Its strongest factor is value.
2256 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $665.94M
- Revenue (TTM)
- $14.32M
- P/E
- —
- EPS
- -0.74
- Dividend yield
- —
- Beta (5Y)
- 1.17
- 52-week high
- HK$18.00
- 52-week low
- HK$7.67
- Avg volume (3M)
- —
- Shares outstanding
- 662.36M
- Employees
- 286
- Next earnings
- —
About Abbisko Cayman Limited
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
- ISIN
- KYG0028A1085
- Founded
- 2016
- Listed since
- Oct 13, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aura Biosciences, Inc.NasdaqGM: AURA | $678.23M | $6.54 | 0.00% |
| Qurient Co., Ltd.KOSDAQ: A115180 | $676.80M | ₩22,350.00 | -9.70% |
| Sunmax Biotechnology Co., Ltd.TPEX: 4728 | $674.51M | NT$396.00 | +0.38% |
| Faeth Therapeutics, Inc.NasdaqCM: FTH | $672.63M | $23.25 | -10.68% |
| Beijing Bohui Innovation Biotechnology Group Co., Ltd.SZSE: 300318 | $646.39M | CN¥5.30 | +1.34% |
| Prime Medicine, Inc.NasdaqGM: PRME | $642.23M | $3.61 | -9.52% |
| Crescent Biopharma, Inc.NasdaqCM: CBIO | $638.16M | $14.46 | -3.02% |
| Medigen Vaccine Biologics CorporationTPEX: 6547 | $637.45M | NT$62.00 | +1.97% |
Figures last refreshed Oct 11, 2026.